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ABSTRACT
FABRICATION AND CHARACTERIZATION OF LACTOBACILLUS CRISPATUSCONTAINING BIOPRINTS FOR BACTERIAL VAGINOSIS APPLICATION

Bacterial vaginosis (BV) is a condition in which healthy lactobacilli are replaced
by an overabundance of pathogenic bacteria in the female reproductive tract. Current
antibiotic treatments often fail to “cure” infection, resulting in recurrence in more than 50%
of women, 6 months post-treatment. Recently, probiotics have demonstrated promise to
restore vaginal health; however, as with other active agents, delivery requires once-to-twice
daily administration. Recently, three-dimensional (3D)-bioprinting has enabled the
fabrication of well-defined cell-laden architectures with tunable agent release, thereby
presenting a novel approach with which to deliver probiotics. One promising bioink,
gelatin alginate, was selected for study, due to its ability in other work to provide structural
stability, host compatibility, viable probiotic incorporation, and nutrient diffusion. The
focus of this study was to formulate and characterize 3D-bioprinted Lactobacillus crispatus
(L.cr.)-containing gelatin alginate scaffolds for reproductive health applications. Different
weight to volume (w/v) ratios of gelatin alginate were bioprinted to determine the
formulation with the highest printing resolution, and different crosslinking reagents were
evaluated for effect on scaffold integrity, via mass loss and swelling measurements.
Additionally, post-print viability, sustained-release, and vaginal keratinocyte cytotoxicity
assays were conducted. A 10:2 (w/v) gelatin alginate formulation was selected based on
line continuity and resolution, while degradation and swelling experiments demonstrated
the greatest structural stability with dual-crosslinking, showing minimal mass loss and
vi

swelling over 28 days. Last, 3D-bioprinted L.cr.-containing scaffolds demonstrated
sustained-release of therapeutically-relevant levels of probiotics over 28 days, while
maintaining the viability of vaginal epithelial cells. For the first time, this study shows that
3D-bioprinted scaffolds may provide a new alternative to sustain probiotic delivery with
future goals to help maintain or restore female reproductive health after BV infection.
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INTRODUCTION

Bacterial vaginosis (BV) is the most common vaginal condition in women of
reproductive age1,2 with a global incidence spanning 23 to 29%3. BV is a chronic
pathophysiological condition that results in an increased diversity of anaerobic and
facultative bacteria, from a typically Lactobacillus-dominant state, to include increasing
numbers of the taxa Gardnerella4-7 and Prevotella within the vaginal microbiome. This
imbalance of pathogenic to beneficial bacteria can result in physiological symptoms that
include greyish discharge and an unpleasant odor and can further lead to serious adverse
health outcomes, including increased risk of sexually transmitted infections; postsurgical
infection8,9; cervicitis and endometritis10,11; pelvic inflammatory disease; cervical cancer;
and preterm birth and pregnancy complications11-24.
Treatments for bacterial vaginosis have only marginally progressed over the last
fifty years25. Current BV treatments comprise the administration of antibiotics alone, or
more recently antibiotics with adjunct probiotic treatment. While FDA-approved
antibiotics, such as metronidazole, clindamycin, and tinidazole, are fairly effective in
treating BV symptoms6,26, they do not cure BV, and treatment failure rates exceed fifty
percent twelve months post-infection, resulting in recurrence in 50-70% of women2. These
outcomes are in part attributed to antibiotics decreasing both beneficial and pathogenic
bacterial viability, enabling pathogenic bacteria to outcompete the growth of beneficial
bacteria in the vaginal microenvironment. Furthermore, in recurrent BV cases, antibiotics
are often prescribed repeatedly, promoting resistance to treatment. Together these factors
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contribute to BV and abnormal vaginal flora recurrence rates as high as 66% and 84%,
respectively27.
Due to the lactobacillus-dominance typically observed in the healthy state, a
potentially promising approach to modulate the vaginal microbiome is to deliver
probiotics, or living microorganisms that can provide health benefits to a host. A variety
of lactobacilli have been considered as promising probiotic options and are believed to
exert activity by producing lactic acid and competing with anaerobes for adherence to the
vaginal epithelium. The increased localized acidity provided by lactic acid decreases the
surrounding pH, making the vaginal environment less hospitable to pathogen survival. In
addition, probiotics may also exert combined antimicrobial and vaginal acidification
effects, helping to restore balance and maintain vaginal health. Probiotics are also viewed
as advantageous to other treatments due to the lack of bacterial resistance and plethora of
natural bacteria to help repopulate the dysbiotic environment.
Studies have shown both oral and vaginal daily probiotic treatments to be effective
in stabilizing bacterial microenvironments in a variety of pathologies, including bacterial
reproductive6,26,28 and bacterial vaginosis infections29-33. Available dosage forms include
topical creams, daily oral supplements, or daily to twice daily vaginal capsules, tablets, or
suppositories5,25,28,34-37. While oral treatments have been shown to deliver probiotics to the
vagina, localized intravaginal delivery is often favored to increase bioavailability and direct
colonization25,28,38-43. A variety of probiotic dosage forms have demonstrated clinical
efficacy in BV treatment32,35,44-46. As one example, vaginal capsules and tablets, loaded
with 108 – 109 colony forming units (CFU) of either one or multiple Lactobacillus strains,
taken one to two times a day, resulted in doubling the clearance rate of BV infection5,25,47.
2

In addition, probiotics have been administered subsequent to antibiotic regimens to help
restore the vaginal environment with beneficial bacteria after BV infection. One study
administered oral clindamycin for seven days, followed by vaginal probiotic capsules for
seven days (109 Lactobacillus casei rhamnosus (LCR35)). After one month, 83% of
patients were reported as “cured” relative to 35% in the control group5. Recently, one of
the most promising options has been shown in staging the delivery of probiotics with the
antibiotic metronizadole, showing a decrease in BV recurrence and increased
efficaciousness in eliminating BV, relative to antibiotic-only treatment5,6,26,28,48.
Despite alleviating initial symptoms and helping to restore the healthy vaginal
environment, challenges exist with current probiotic (and antibiotic) dosage forms, which
rely on frequent daily administration to obtain therapeutic effect. These dosing regimens
may be inconvenient for many women, and lead to a lack of compliance that has adverse
effects on efficacy. Additionally, barriers to convenience and ease-of-use, such as
messiness, leakage, and unfavorable discharge, impact user adherence and treatment
efficacy5,7,42,49-52.

Relative to the transient administration provided by tablets,

suppositories, creams, and gels, one of the few platforms that has been designed to sustain
probiotic31,53-57 (and other active agent53,58,59) delivery is the intravaginal ring (IVR). To
our knowledge, pod-based IVRs containing lyophilized L. gasseri, are the only technology
designed to-date to provide localized and sustained probiotic delivery in vitro60.
Relative to the mold-based and often multi-step techniques typically involved in
IVR fabrication, 3D-bioprinting enables the rapid manufacturing of scaffolds that have
historically been used to support or viably incorporate mammalian cells for a variety of
biomedical applications. While bioprinted scaffolds have been more frequently developed
3

as cell scaffolds, a variety of bioinks have incorporated different cell types in a highthroughput method61,62. In particular, bioinks composed of gelatin and alginate have been
shown to promote high cell viability, scaffold stability, nutrient diffusion, and co-delivery
of multiple agents63-66. In parallel, technical advances have enabled the printing of diverse
materials in spatially distinct layers to provide temporally modulated delivery regimens.
Moreover, successes in attaining cell proliferation and differentiation for tissue engineering
applications indicate significant potential for probiotic cells to similarly undergo
proliferation with the potential for probiotic “release” from the scaffold and concomitant
restoration of a healthy vaginal environment. Yet, to date, few studies have incorporated
prokaryotic cells during scaffold bioprinting67-74.
Given the lack of probiotic-containing sustained-delivery dosage forms, the goal of
this study was to develop a new 3D-bioprinted dosage form to enable viable and prolonged
probiotic delivery.

In this study, we evaluated scaffold formulation, printability,

degradation, and probiotic proliferation and release kinetics from the scaffold. Ideal design
criteria of 3D-bioprinted constructs included high line resolution with minimal line
agglomeration, structural stability, high bacterial viability, and sustained probiotic release
and/or proliferation at therapeutically relevant concentrations for a minimum of one week.
We anticipate that these studies will provide a foundation for future sustained-release
probiotic delivery vehicle design, to eventually provide an alternative approach to treating
BV and restoring vaginal health.
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MATERIALS AND METHODS

2.1 Materials
Lactobacillus crispatus (MV-1A-US) was purchased from BEI Resources. De
Man, Rogosa, and Sharpe (MRS, Sigma 69966) broth; simulated vaginal fluid (SVF)
composed of NaCl, KOH (Sigma, P-6310), Ca(OH)2 (Sigma, 31219-100G), bovine serum
albumin (Fisher, BP1600-100), lactic acid (Alfa Aesar, 36415), acetic acid (Fisher, A38500), glycerol (VWR, M152-1L), urea (Alfa Aesar, A12360), and glucose (Sigma, G70211Kg); and phosphate buffer solution (PBS) composed of NaCl (VWR, 0241-1kg), KCl
(Fisher, P217-500), Na2HPO4 (Sigma, S9763-100G), and KH2PO4 (Sigma, P5655-100G)
were purchased to formulate release eluants. Genipin and calcium chloride (CaCl2) were
obtained from Sigma Aldrich (St. Louis, MO). Simulated vaginal fluid was prepared as
mentioned in75.

2.2. Probiotic Culture
L. crispatus was initially cultured on MRS (supplemented with 0.1% Tween 80)
agar plates under anaerobic conditions at 37°C, and colony formation was observed after
48 hr. L. crispatus was then sub-cultured by selecting a single colony from the agar plates
and culturing in 1 mL of MRS broth in a closed microcentrifuge tube at 37°C for an
additional 48 hr. Subsequent sub-cultures were established by diluting 200 µl of L.
crispatus with 9.8 mL of MRS broth (1:50).

2.3 Bioink Preparation and Probiotic Incorporation
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Bioinks were formulated from gelatin from bovine skin (Sigma, G9391-100G) and
sodium alginate (MP Biomedicals, 218295). Several different ratios of gelatin to alginate
were tested, as most literature sources utilized 10 to 20% w/v gelatin and 1 to 5% w/v
alginate to print mechanically stable constructs66,76-78. MRS broth was used to dissolve the
gelatin and sodium alginate in ratios of 10:1, 10:2, 11:2, 12:2, and 16:4 (w:w)/volume of
MRS (hereafter w/v), followed by overnight incubation at 37°C. Bioinks were then
removed from the incubator, vortexed, and rested for 5 min before transferring to a syringe
for subsequent bioprinting.

To fabricate L. crispatus-containing scaffolds, a L. crispatus sub-culture was
diluted 1:10 in PBS. A Nanodrop 2000 (Thermo Scientific, MA) was utilized to measure
the absorbance value (OD600) to determine the volume of L. crispatus solution to add to the
bioink, using the equation y = ((9 x 107) * (x)) – 2 x 107 to obtain a theoretical loading of
5 x 107 CFU per mg scaffold. The appropriate volume of L. crispatus solution was
centrifuged (3500 × g, 10 min), supernatant was removed, and the pellet was resuspended
in 500 µL of MRS. The bacteria were then added to 4.5 mL of prepared bioink and the
bacteria-bioink mixture was transferred to a syringe for bioprinting. The CORE head of an
Allevi 3 Bioprinter (Allevi, Inc., Philadelphia, PA) was heated to 37°C prior to bioprinting.

2.4 Bioprinting and Crosslinking of the Scaffolds
The Allevi 3 Bioprinter was used to bioprint blank and L. crispatus-containing scaffolds.
The 3D bioprinter was calibrated, and processing parameters including extruder
temperature, pressure, and printing speed were optimized for printing.
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The extruder temperature was set at 37°C to decrease bioink viscosity and to simulate the
physiological environment, while the initial extruding pressure was adjusted between 32
and 42 psi79. Gelatin to sodium alginate ratios of 10:1, 10:2, 11:2, 12:2, and 16:4 w/v were
initially printed in layer thicknesses of 200 µm with a 30G (152 µm inner diameter) needle
to determine the printing formulation that provided the most accurate line resolution.
Bioinks were loaded into 1 mL plastic syringes with a spatula, the syringe was placed in
the extruder, and five different line formulations were printed to assess printing feasibility
and resolution.

An extruded bioink formulation that displays consistent dimensions with the print
files will validate and enable the printing of more complex architectures. After determining
the formulation that resulted in bioprints with accurate measurements of the desired
construct, the needle gauge was varied to determine the effect on line resolution. Bioinks
formulated in a 10:2 w/v ratio were printed with a 26, 30, or 34-gauge luer lock needle
attached to the syringe. The pressures and extrusion rates were adjusted to adapt to the
changes in shear stress resulting from different needle diameters. Circle-shaped lattices
were printed with diameters of 30, 15, and 8 mm to determine resulting print resolutions
with different needle gauges. Additionally, for each different lattice diameter/needle
combination, scaffolds were printed with 1, 2, and 3 mm thicknesses. These circular lattice
structures were printed with pre-made GCODE files that specified print dimension and
geometry.
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Printing parameters, determined from these experiments, were used to inform and
fabricate subsequent intravaginal ring-type designs. The high-resolution circle-shaped
lattice prints helped to inform the needle gauge needed to print a simpler, more application
appropriate intravaginal ring shape.

After determining the optimal parameters of formulation and needle gauge that best
represented the input dimensions of diameter, line width and thickness, scaffolds were
printed in intravaginal ring-shaped geometries to represent currently accepted dosage
forms. The IVR scaffolds were printed using a customized STereoLithography (STL) file
specifying an outer diameter of 4 mm and inner diameter of 3 mm. The optimized bioink
used for printing contained 5 x 107 CFU/mg of L. crispatus at a 10:2 gelatin to sodium
alginate ratio. The homogenous bioink was transferred to the bioprinting syringe at a
volume of 1 mL. Prior to printing, the CORE head of the Allevi 3 bioprinter was heated to
37°C to maintain an ideal physiological environment for L. crispatus. The extruder
pressure was adjusted to 42 psi for a 30G needle to print constructs with accurate
dimensions stated in the printing file.

Subsequent to printing, both blank and L. crispatus containing IVR-shaped
scaffolds were placed in the refrigerator (4°C) for 15 min to harden. Two different
crosslinkers, genipin and CaCl2, were then used to crosslink the gelatin and alginate
portions of the scaffold, respectively. Genipin has been shown to improve the mechanical
and thermal properties of gelatin while maintaining drug permeation capabilities80, as well
as prolonging its degradation time81, while CaCl2 relies on ionic crosslinking to form a
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stable three-dimensional network providing mild reaction conditions, greater aqueous
permeability, and increased stability of alginate after immersion in solute82-84.

A variety of crosslinking conditions were evaluated to assess the effect of
crosslinking molecule and time on scaffold integrity and probiotic viability: genipin-only
(4 hr), genipin-only (24 hr), CaCl2-only (20 min), CaCl2 (20 min) and genipin (4 hr), and
CaCl2 (20 min) and genipin (24 hr). Uncrosslinked scaffolds were made for comparison to
the crosslinked groups. For dual-crosslinked scaffolds, CaCl2 crosslinking was conducted
prior to genipin crosslinking. Briefly, 20 mL of 10% w/v CaCl2 in DI water were poured
on the chilled scaffolds in a petri dish and scaffolds were chilled at 4°C for 20 min. Next,
5 mL of 0.5% w/v80,85 genipin in 1x PBS was poured on the chilled scaffolds and incubated
at room temperature for 4 or 24 hr86. Crosslinked scaffolds were then washed three times
with DI water and placed back in the refrigerator until use. For CaCl2-only or genipin-only
crosslinked control groups, scaffolds were crosslinked and incubated for the durations and
temperatures defined above.

2.4 Viscosity
Bioink viscosity was determined for the 10:2 w/v blank and L. crispatus-containing
gelatin alginate formulations to ensure consistent bioink extrusion and resulting
mechanically stable scaffolds. Similarly, 16:4 w/v bioinks served as a control group to
compare difficult-to-print formulations. A DVE viscometer (AMETEK Brookfield, MA)
was used to assess bioink viscosity and a rechargeable temperature data logger (Omega,
CT) was used to measure the temperature with respect to time. Initially, 10 mL of the 10:2
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gelatin alginate bioink was aliquoted to a scintillation vial and incubated at 37°C. The S63
spindle was submerged into the bioink with spindle top 1 mm above surface, and
temperature sensors were placed in the bioink to simultaneously record changes in
viscosity and temperature. The viscometer was set to 20 rpm, and the viscosity was
measured as a function of temperature.

2.5 Degradation and Swelling
To assess mass loss, crosslinked scaffolds were dried at 50oC overnight to ensure
scaffolds were fully dry, and the initial dry weight of the samples (Wi) was measured.
Scaffolds were then immersed in 1.5 mL of SVF for 0, 4, 8, 24, 72, 120, and 168 hr, and
2, 3, and 4 wk, after which the final sample weight (Wf) was measured. The mass loss
percentage were determined according to Eq. (1):

Mass Loss Percentage = [(Wi-Wf)/Wi]×100

(1)

To assess scaffold swelling, the initial mass of the crosslinked scaffolds (Wi) was
measured. Scaffolds were then placed in microcentrifuge tubes containing 1.5 mL SVF.
Scaffold weights were evaluated at 0, 24, 48, 72, 96, 120, 144 and 168 hr, and 2, 3, and 4
wk. At each time, scaffolds were removed, dried, and weighed to obtain the corresponding
weight (Ws). The percent of mass change relative to initial mass was determined according
to Eq. (2):

Mass Swelling Percentage = [(Ws-Wi)/Wi]×100
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(2)

2.6 Initial Loading and Viability of Bacteria
After bioprinting, uncrosslinked blank and L. crispatus-containing scaffolds were
assessed for loading after crosslinking for 0, 25, and 60 min at 4°C, conditions relevant to
CaCl2 crosslinking. Then pre-weighed samples were placed in 1 mL MRS broth at 37°C.
After scaffold dissolution, the tubes were gently vortexed and the 20 µL was serially diluted
in 180 µL MRS broth. Aliquots of 5 µL were plated on MRS agar plates, placed in the
anaerobic chamber for 48 hr, and the number of CFUs was counted.

2.7 Quantification of Probiotic Release and Proliferation from Printed Scaffolds
The release and proliferation of L. crispatus from crosslinked scaffolds were
evaluated in MRS broth for up to 4 wk. Pre-weighed scaffolds were placed in 1.5 mL
microcentrifuge tubes and incubated in 1.5 mL MRS at 37°C with constant shaking at 150
rpm. The supernatant of each sample was removed after 0, 4, 8, 24, 72, 120, 144, and 168
hr, and 2, 3, and 4 wk, and sample eluate was diluted by adding 20 µL of sample to 180 µL
of MRS broth. Five µL of each sample dilution were plated on MRS agar plates and placed
in an anaerobic chamber for 48 hr. After 48 hr, the plates were evaluated for CFU counts.
After each collection, the scaffolds were washed four times in 5 mL PBS, placed in 1.5 mL
fresh MRS broth, and incubated until the next time point.

2.8 Quantification of Lactic Acid and pH
Scaffold release eluates, collected at the corresponding probiotic release time points
(0, 24, 48, 72, 96, 120, 144, and 168 hr, and 2, 3, and 4 wk) were evaluated for lactic acid
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production and resulting pH change. Briefly, 1 mL of eluate was centrifuged at 2500 x g
for 5 min to separate the bacteria from the solution and then the solution was serial diluted
using 10-fold dilutions. The concentration of L- and D-lactic acid was determined with a
lactic acid detection kit (R-biopharma; Darmstadt, Germany) and the corresponding pH of
eluates at each time point was measured using pH strips with a pH range of 1 to 6 and an
accuracy of 0.5 pH units (Fisher Scientific).

2.9 Probiotic Stability in Bioprinted Scaffolds after Storage
The temperature stability of L. crispatus formulated in 10:2 gelatin:alginate
bioprinted scaffold was tested by CFU counting on MRS agar, as described above.
Scaffolds containing L. crispatus were stored in sealed Petri dishes at either -20°C, 4°C,
or 20°C, and probiotic viability evaluated for up to 4 wk. After 1, 2, and 4 wk, the stored
bioprinted scaffolds were placed in microcentrifuge tubes and incubated in fresh 1.5 mL
MRS broth for 30 min at 37°C with constant shaking at 150 rpm to assess daily release
from the scaffold. The release was then diluted using 10-fold serial dilutions, 5 µL was
plated on MRS agar plates, and CFUs were counted after 48 hr of anaerobic incubation at
37°C.The cumulative release and proliferation of L. crispatus in MRS from scaffolds were
evaluated for and compared to scaffolds assessed immediately post-fabrication.

2.9 Scaffold Morphology
The morphology of the blank and L. crispatus-containing scaffolds was
characterized using scanning electron microscopy (SEM). Scaffold cross-sections were
placed on carbon tape, sputter-coated with a layer of palladium/gold alloy (8.5 nm), and
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imaged using Apreo C LoVac Field Emission SEM (Thermo Scientific, Waltham, MA).
Proliferation was compared in scaffolds that were immersed in timepoints at 0, 1, and 7
days in MRS and SVF.

2.10. VK2/E6E7 Viability
An MTT assay was used to determine the preliminary in vitro safety of CaCl2
and genipin crosslinked, blank and L. crispatus-containing scaffolds, in a VK2/E6E7 cell
line. Cells were plated at a density of 300,000/well in a 12-well plate and incubated for 24
hr at 37°C. Media only (untreated cells) and 10% DMSO were used as viable and nonviable cell controls. After 24 and 72 hr incubation, 100 µL of MTT labeling reagent was
added to each well and incubated at 37°C for 4 hr, followed by adding 100 µL of lysis
buffer containing 10% sodium dodecyl sulfate and 0.01 M hydrochloric acid. After 16 hr
incubation, the absorbance was read at 570 nm (SYNERGY Microplate Reader, Biotek
Instruments Inc) and normalized to cell-only absorbance to attain the relative percent of
cell viability.

2.10 Statistical Analysis
All experiments were done in triplicate, and Minitab (Minitab, LLC, State College,
PA) and GraphPad (GraphPad Software, La Jolla, CA) were used in statistical analysis.
Three replicates were used for each sample and were subjected Grubbs’ test (p ≤ 0.05) to
determine outliers. All statistical analyses in

GraphPad Prism (version 9.3.1) were

performed using one-way ANOVA with the Tukey multiple comparison’s test (p ≤ 0.05).
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RESULTS

3.1 Bioprinting Probiotic Scaffolds
The optimal bioink formulation and printing parameters were determined by
evaluating the printing resolution, mechanical integrity, and probiotic loading in probioticcontaining scaffolds. The bioink formulation ratio was varied to assess its impact on line
resolution and scaffold integrity with a standard-gauge needle after printing.

First, the line resolutions of blank and L. crispatus-containing gelatin:alginate
(10:1, 10:2, 11:2, 12:2, 16:4 (w:w)/v (hereafter w/v) formulations were evaluated (Figure
1). An image of the Allevi bioprinter and bioprinted lines resulting from initial prints are
shown in Figure 1A and B. Overall, the 10:2 and 12:2 w/v blank formulations were found
to provide the most line continuity and closest line resolution relative to input dimensions,
whereas the 10:1 and 11:2 formulations resulted in thicker and thinner lines, respectively.
In comparison, the 16:4 formulation resulted in some line fragmentation, with an overall
asymmetrical and jagged line appearance.

Upon addition of L. crispatus, the 10:1, 11:2, and 12:2 w/v formulations resulted in
line broadening, in addition to line fragmentation and inconsistent extrusions, while the
16:4 w/v formulation continued to display asymmetrical and jagged morphology. Overall,
the 10:1, 11:2, and 12:2 w/v prints showed a 2-fold increase in width when L. crispatus
was incorporated (spanning ~0.90-1.65 mm, with respect to the input line width of 0.68
mm), contributing to a decrease in line resolution. In contrast, the 10:2 w/v blank and L.
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crispatus-containing bioinks exhibited the finest line resolution and ability to maintain
structural integrity after L. crispatus incorporation, with line widths of 0.76 ± 0.06 mm and
0.78 ± 0.03 mm, respectively, corresponding to a design specification of 0.68 mm.
Therefore, the 10:2 formulation was selected for subsequent studies.

FIGURE 1: EXPERIMENTAL SETUP AND LINE RESOLUTION
Figure 1. Experimental setup and representative images of gelatin alginate scaffolds
bioprinted with different formulation ratios. (A) Image of the Allevi 3D bioprinting setup
and components. Briefly, the bioink is loaded into a dispensing syringe that is attached to
a luer-locked needle in the CORE head and extruded into a petri dish. (B) Representative
line prints of the 10:1, 10:2, 11:2, 12:2, and 16:4 w/v blank and L.cr.-containing gelatin
alginate formulations extruded at 42 psi and 37°C with a 30G needle, shown immediately
post-print. Coded file line width was defined as 0.68 mm. The 10:2 ratio provided line
resolutions closest to CAD drawing specifications for both the blank and L. cr.-containing
scaffolds. Scale bar represents 1 mm.
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Next, the effects of needle gauge and L. crispatus addition were evaluated for the
10:2 formulation. A variety of circle-shaped lattice structures were printed with varying
diameters and thicknesses, with 26G, 30G, and 34G needles (Figure 2). Blank and L.
crispatus-containing bioprints are shown in Figures 2A-D and 2E-H, respectively.
Scaffold diameter and thickness were varied between 8, 15, and 30 mm and 1, 2, and 3 mm
(here, for each 3x3 panel).

Overall, uniform bioink extrusion was achieved using pressures of 42 and 115 psi
and 30G and 34G needles, respectively, while well-defined structures were unachievable,
in particular for L. crispatus-containing with the larger 26G needle, regardless of the
pressure. For most bioprints, the 34G needle maintained infill spaces and resolution of both
blank and L. crispatus-containing lattice structures, whereas the 26G and 30G needles
resulted in amorphous lattice structures for the L-crispatus-containing lattice structures.
Based on these observations, the 34G needle was used to print subsequent scaffolds.

In parallel, printing integrity was evaluated as a function of L. crispatus loading
(107, 108, and 109 CFU per mg scaffold) as a function of scaffold thickness and diameter
(Figures 2I and J). The thicknesses and diameters of the resulting scaffolds were measured
at 4 different positions within the circle-shaped structures as a function of probiotic
concentration. Generally, as probiotic concentration increased, scaffold thickness and
diameter increased (Figures 2I and J). As one example, 8 mm diameter scaffolds printed
with thicknesses of 2 mm, showed an initial thickness of 1.82 mm for blank scaffolds,
subsequently increasing to 1.92, 2.05, and 2.31 mm for 107, 108, and 109 CFU L. crispatus
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per mg scaffold. Additionally, as the input scaffold thickness increased from 1 to 3 mm,
the deviation in thicknesses increased for blank and L. crispatus-containing formulations,
signifying less accuracy in print resolution.

FIGURE 2: REPRESENTATIVE IMAGES OF SCAFFOLDS
Figure 2. Representative images from (A-D) blank and (E-H) L. crispatus-containing
scaffolds that were bioprinted using a 10:2 w/v gelatin alginate bioink. Scaffolds were
printed using 26, 30, and 34G needles and extrusion pressure was adjusted to compensate
17

for different needle gauges. Blank or L. crispatus-containing scaffolds were printed with
(A, E) 30 mm, (B, F) 15 mm, and (C, G) 8 mm diameters. Within each panel, the input
thickness of printed scaffolds increased from 1 to 3 mm (left to right). Panels D and H
show blank and L. crispatus-containing ring structures fabricated with 3 and 4 mm ID/OD.
Scale bars represent 10, 5, 3 and 2 mm from left to right. The reproducibility in (I) thickness
and (J) diameter of blank and L. crispatus-containing scaffolds were measured as a function
of probiotic incorporation. Panel I shows the measured thicknesses from 8 mm diameter
scaffolds printed with 1, 2, and 3 mm thicknesses. Panel J shows the measured diameters
from 1 mm thick scaffolds printed with 8, 15, and 30 mm diameters.

Somewhat similar trends were observed for 1 mm thick scaffolds printed with a 15
mm diameter. The average printed diameter of 15 mm scaffolds increased from 14.97 mm,
for blank scaffolds to 14.52, 16.18, and 18.38 mm for scaffolds containing 107, 108, and
109 CFU L. crispatus per mg scaffold. Scaffolds printed in 8 and 30 mm diameters showed
minimal changes in diameter as a function of probiotic incorporation, with statistical
significance observed only for the 8 mm diameter scaffolds (blank to 109 CFU/mg).
Overall, scaffolds containing 107 CFU/mg provided the closest lattice print dimensions in
both thickness and diameter to blank scaffolds. Moreover, the impact of L. crispatus
concentration was more significant when considering thickness of scaffolds, leading to less
reproducibility and maintenance of line resolution at increased scaffold thicknesses and
probiotic concentration. To maximize loading, while still achieving printing accuracy,
subsequent scaffolds were printed with 5x107 CFU L. crispatus/mg.

18

3.2 Viscosity
Bioink viscosity was evaluated as a function of temperature for the 10:2 and 16:4
w/v (control) blank and L. crispatus-containing formulations, due to the temperature
dependence of probiotic viability. At 37°C, the viscosities of 10:2 w/v blank and L.
crispatus-containing (5 x 107 CFU/mg) gelatin alginate bioinks were 1171 ± 17 cP and
1616 ± 19 cP, respectively. As the temperature decreased from 37°C to 28°C, both blank
and L. crispatus-containing 10:2 formulations showed steady increases in viscosity,
resulting in viscosities of 1989 ± 23 and 2501 ± 19 cP, respectively. (Supplementary
Figure 1). Similar trends were observed with the 16:4 w/v formulation, however the initial
viscosities (at 37°C) of blank and L. crispatus-containing (5 x 107 CFU/mg) bioinks were
much higher with values of 154,500 ± 13,352 and 125,167 ± 1,258 cP. As the temperature
decreased from 37°C to 30°C, blank and L. crispatus-containing 16:4 formulations showed
an initially steady increase in viscosity, after which the L. crispatus-containing bioink
showed a sharp increase in viscosity. At 28°C, the blank and L. crispatus-containing
bioinks had viscosities of 270,000 ± 27,839 and 507,167 ± 55,219, respectively. Overall,
both the 10:2 and more viscous, 16:4, formulations showed similar trends of increasing
viscosity as a function of decreasing temperature; however, the 16:4 formulation exhibited
more than a 100-fold increase in initial and final viscosities.
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SUPPLEMENTARY FIGURE 1: VISCOSITY OF BIOINKS
Supplementary Figure 1. The viscosity of (A) 10:2 and (B) 16:4 w/v gelatin alginate
formulations shown from 28°C to 37°C. Viscosity was measured every 1°C.

3.3 Scaffold Degradation and Swelling as a Function of Crosslinking Conditions
Multiple crosslinking conditions were evaluated to determine the crosslinking
conditions and duration that resulted in the least mass loss and degradation (Figure 3).
Dual-crosslinking with CaCl2 followed by genipin was found to be the most resistant to
degradation over 28 days (Figure 3A), while crosslinking solely with CaCl2 (data not
shown) or genipin-only resulted in degradation within 1 or 7 d, respectively. Furthermore,
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scaffolds crosslinked with genipin-only were fully degraded within 7 d, independent of 4
or 24 hr crosslinking duration. Similarly, dual-crosslinking with both CaCl2 and genipin
for only 4 hr resulted in rapidly degraded structures, on the order of 7 d, while dualcrosslinking for 24 hr resulted in intact structures over 28 d (Figure 3A).

In parallel with macrostructural observations, scaffold degradation was quantified
by measuring the mass loss of oven-dried scaffolds with respect to time (Figure 3B). The
average mass of the dual-crosslinked scaffold printed with 5 x 107 CFU L. crispatus/mg
was 2.21 ± 0.25 mg. Overall, initial mass loss occurred within the first 4 to 8 d, and
stabilized after these durations. After 24 hr, dual-crosslinked and genipin-only crosslinked
scaffolds (crosslinked for 24 hr) lost 16 and 19% of their initial masses, respectively. After
28 d, small differences in mass loss were observed between dual- and genipin-only
crosslinked scaffolds (p ≤ 0.0001), with total mass losses of 25% and 38% of initial masses,
respectively.

In parallel with mass loss measurements, scaffold swelling was quantified by
measuring the mass of tissue-blotted scaffolds relative to their initial mass (Figure 3C).
After 24 hr, dual-crosslinked scaffolds exhibited 18% mass loss, relative to the 24% mass
loss observed after crosslinking with genipin-only. After 28 d, both dual- and genipin-only
crosslinked scaffolds showed mass losses of 45%. Overall, minimal differences in scaffold
swelling, as measured by mass change, were observed between dual- and singlecrosslinked groups.
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FIGURE 3: SCAFFOLD DEGRADATION AND SWELLING
Figure 3. Scaffold degradation and swelling were evaluated as a function of crosslinker
and crosslinking duration. (A) Representative images of ring-shaped L. crispatuscontaining scaffolds (OD: 4 mm, ID: 3 mm) printed with 5×107 CFU L. crispatus per mg
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scaffold and crosslinked with genipin-only or both CaCl2 and genipin for 4 or 24 hr.
Scaffold macrostructure was evaluated after incubation in 5 mL MRS media after 0 and 4
hr, and 7 and 28 days. Scale bar represents 4 mm. Scaffolds printed with CaCl2-only
dissolved immediately upon exposure to media (not shown). (B) Scaffold mass loss,
attributed to degradation, and (C) scaffold swelling, both shown as the percent of initial
mass, for scaffolds dual-crosslinked with CaCl2 and genipin or genipin-only for 24 hr, were
evaluated for 28 d in SVF. Degradation and swelling (mass loss) values are shown as the
mean ± standard deviation from five independent ring scaffolds. Statistical significance
between experimental groups, as calculated by one-way ANOVA, is represented by *p ≤
0.05 and ****p ≤ 0.0001.

3.4 L. crispatus Viability and Release
Bioprinted scaffolds containing 1x107, 5x107, and 1x108 CFU L. crispatus per mg
scaffold were evaluated for probiotic viability after 0, 25, 60 min. at 4°C to evaluate the
impact of potential CaCl2 crosslinking durations on probiotic viability (Figure 4A). The L.
crispatus-containing scaffolds maintained L. crispatus viability at each loading
concentration, independent of crosslinking duration at 4°C. Overall, a slight increase in
viability was observed between the unprinted blank scaffold control group and blank
scaffolds crosslinked for 0, 25, or 60 min durations (p ≤ 0.01). Furthermore, it is visually
evident that the architecture of blank and L. crispatus-containing scaffolds remain intact
after immersion in SVF for 28 d (Figure 4B).
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In addition, the cumulative and daily release of probiotics from L. crispatuscontaining scaffolds was evaluated over 4 wk (Figure 4C and D). After 24 hr and 14 d,
cumulative probiotic release (and proliferation) from the scaffolds reached 108 and 5x109
CFU/mg, while after 28 d, concentrations reached 1010 CFU/mg. Daily release showed
relatively steady concentrations of approximately 4 x108 CFU/mg released per day.

Last, the pH-modulation of L. crispatus-containing dual- and genipin-only
crosslinked scaffolds was assessed by measuring the pH of release eluate after daily media
changes (Figure 4E). In congruence with release results, a decrease in pH (from 6 to 3.5)
was observed from the dual-crosslinked scaffold eluates after ~4 d immersion. Genipinonly scaffolds showed a slightly more gradual decrease in pH, achieving comparable pH
levels (3.5) after 5 d. Both scaffolds demonstrated vaginally-relevant pH values after ~4 or
5 d, indicative of probiotic viability and lactic acid production.
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FIGURE 4: SCAFFOLD VIABILITY, STRUCTURAL INTEGRITY, RELEASE, AND
MODULATION
Figure 4. Bioprinted scaffolds were assessed for L. crispatus viability, structural integrity,
cumulative and daily release, and resulting pH modulation. (A) The post-print viability of
L. crispatus, based on theoretical loadings of 1x107, 5x107, and 1x108 CFU L. crispatus/mg
scaffold is shown for uncrosslinked scaffolds (relative to unprinted bioinks) that were
dissolved in MRS after different durations of crosslinking at 4°C. (B) Representative
images of blank or L. crispatus-containing (5×107 CFU/mg) ring-shaped scaffolds dual25

crosslinked with CaCl2 followed by genipin for 24 hr, and after different immersion
durations in SVF (1, 7, 14, 28 d). Scale bar represents 5 mm. (C) The cumulative and (D)
daily release and proliferation of L. crispatus from crosslinked scaffolds. Values are shown
as the mean ± standard deviation from five independent ring-shaped scaffolds. (E) The
resulting pH of the release eluate measured and values are shown as the mean ± standard
deviation of eluates from three scaffold batches. Error bars are displayed but are smaller
than the symbol size. Statistical significance between experimental groups, as calculated
by one-way ANOVA, is represented by **p ≤ 0.01, ***p ≤ 0.001 and ****p ≤ 0.0001.

3.5 Stability of L. crispatus Release in Scaffolds
The stability of L. crispatus was assessed by measuring its release from scaffolds
after storage at -20°C, 4°C, and 20°C for 4 wk (Figure 5). After storage at -20°C for
multiple weeks (Figure 5A), scaffolds demonstrated viable probiotic release, similar to
freshly made unstored scaffolds. After storage at 4°C, samples stored for 1, 2 and 4 wk
showed a slight reduction in viability, relative to fresh scaffolds, but similar viability with
respect to each other (Figure 5B, p ≤ 0.01, p ≤ 0.01, and p ≤ 0.001, respectively). Lastly,
scaffolds stored at room temperature for one week (Figure 5C) showed no indication of
release and viability, relative to probiotic release from fresh scaffolds, indicating
significant decreases in probiotic viability for all storage durations (p ≤ 0.0001).
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FIGURE 5: SCAFFOLD STABILITY
Figure 5. The stability of dual-crosslinked scaffolds (CaCl2 + genipin, 24 hr) after storage
for 1, 2, and 4 wk in (A) freezer (-20 °C), (B) refrigerator (4 °C), and (C) room temperature
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(20°C) conditions. Release values are shown as the mean ± standard deviation of L.
crispatus from the eluates of three independent ring-shaped scaffolds. In some cases, error
bars are smaller than the symbol size. Please note overlap in all symbols except for the
fresh scaffold in panel C. Statistical significance between experimental groups, as
calculated by one-way ANOVA, is represented by **p ≤ 0.01, ***p ≤ 0.001, and ****p ≤
0.0001.

3.6 Scaffold Characterization
The SEM images of blank and L. crispatus-containing scaffolds, dual-crosslinked
for 24 hr, are shown in (Figure 6). Proliferation, relative to that in blank scaffolds, was
visually evident from cross-sectional images between 1 and 7 d. The presence of L.
crispatus on the interior cross-section demonstrates the potential of L. crispatus to
proliferate in the bioprinted scaffolds.

FIGURE 6: SCAFFOLD CROSS SECTION IMAGING
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Figure 6. Scanning electron microscopy images of probiotic scaffold loaded with 5×107 of
L. crispatus. Top and bottom images show cross-sections of blank and L. cr.-containing
scaffolds, respectively. The interior IVR cross-sections are shown after different release
time points. Scale bar represents 5 µm.
3.7. VK2/E6E7 Viability
The viability of vaginal keratinocytes (VK2/E6E7) was evaluated after treatment
with blank and L. crispatus-containing scaffolds, crosslinked with different crosslinkers
(Figure 7). Vaginal keratinocyte viability was maintained after 24 and 72 hr treatment
with all scaffold groups, relative to untreated VK/E6E7 cells. Blank genipin-only and
dual-crosslinked L. crispatus-containing scaffolds maintained greater than 96% cell
viability over 24 and 72 hr treatment conditions. Uncrosslinked and CaCl2-only
crosslinked blank scaffolds showed slight increases in viability after 24 and 72 hr,
relative to untreated cells (p ≤ 0.01 (uncrosslinked 24 hr) and p ≤ 0.0001 (other groups)).
In contrast, cell viability for the negative control group, 10% DMSO, had viabilities of 28
and 33% of that observed with untreated cells (p ≤ 0.0001).

FIGURE 7: CELL VIABILITY
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Figure 7. Cell viability of vaginal keratinocytes (VK2/E6E7 cells) that were treated with
bioprinted scaffolds for 24 or 72 hr. Negligible cytotoxicity was observed in VK2/E6E7
cells administered IVRs that were processed with different crosslinking conditions.
Statistical significance between experimental groups, as calculated by one-way ANOVA,
is represented by **p ≤ 0.01 and ****p ≤ 0.0001.
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DISCUSSION

The administration of probiotics has been shown to be a promising new alternative
to antibiotics to treat BV5,32,35,44-46. Probiotics have been shown to restore and maintain
vaginal health by promoting increased immune cell activity, antimicrobial production,
reduction of vaginal pH, and competition for nutrients against pathogenic anaerobes in the
vaginal microbiome5,89,90. Additionally, an increase in cure rate as well as reduction of
recurrence has been observed with adjunct probiotic therapy30,33,47,91,92. Apart from other
probiotic species, L. crispatus has seen clinical relevance presumably due to its underlying
presence in the healthy vaginal environment. L. crispatus has been a prominent probiotic
candidate to treat BV and recurrent infections through its ability to produce lactic acid and
modulate the acidic pH of the vaginal environment93,94. Additionally, L. crispatus has been
shown to stimulate the release of pro-inflammatory mediators and autophagy in vaginal
epithelial cells95-97.

Although probiotic therapy has shown promise, one of the primary challenges in
both oral and intravaginal delivery is in promoting user adherence. In particular, the
frequent, once-to-twice daily administration needed for antibiotic and probiotic therapy can
result in low user adherence and hence, inadequate treatment outcomes. For this reason,
one potential solution is to develop sustained release dosage forms that enable the
prolonged delivery of active agents, such as probiotics, over a duration of days to weeks.
To date, vaginal tablets, gels/creams, films, capsules, microparticles, intravaginal rings
(IVRs), and suppositories have been locally delivered to the female reproductive tract;
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however, pod-based IVRs containing lyophilized L. gasseri, are the only platform shown
to provide sustained probiotic delivery in vitro31,60.

Recently, 3D bioprinting has emerged from additive manufacturing as a new
alternative with which to fabricate materials for broad applications including tissue and
organ regeneration, biological implants, and drug and biologic delivery62,67,68,71,72,98,99.
Specifically for the delivery of live cells, bioprinting has shown a highly viable method
with which to incorporate and deliver live cells from a variety of materials. In 3D
bioprinting, cell-containing bioinks can be extruded at temperatures and pressures that are
compatible with physiological conditions, while maintaining cell viability, in an
aseptic/sterile environment100-102. Due to its success in incorporating both eukaryotic and
prokaryotic cells63-66,69,103,104, we sought to apply bioprinting to develop a novel probioticcontaining scaffold that could prolong probiotic release for durations of days to weeks.

A variety of bioinks have been used for biological printing, some of which include
collagen, gelatin, fibronectin, laminin, chitosan, alginate, and silk fibroin105. For this initial
work, gelatin alginate was selected due to its proven ability in early work to bioprint
eukaryotic cells for grafting and regenerative medicine applications63-66, and more recently
to deliver viable and stable prokaryotic cells, while maintaining scaffold integrity69,103,104.
More broadly, bioprinting has enabled the potential to create precisely designed scaffolds
that adopt a streamlined additive manufacturing process, enable the incorporation of
biologics, and are relatively inexpensive and rapid to fabricate, relative to custom molding
processes68,69,73. Furthermore, bioprinting enables the user to customize architectures to
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match user preference and to tune release of active agents in personally tailored products.
The expansion of bioprinting to female reproductive applications and more specifically
infections, may offer a novel and alternative method with which to increase clinical
effectiveness, help restore vaginal health, and address recurrent infections in women’s
health.

In this study, we began by assessing the reproducibility of bioprinting different
gelatin alginate formulations with and without the incorporation of probiotics. Bioink
homogeneity is an important parameter, first to attain uniform printability and second, to
enable nutrient diffusion and hence L. crispatus viability in the bioink during and postprinting. First, a variety of gelatin alginate formulations were evaluated to determine the
changes in line printing resolution and morphology when L. crispatus was incorporated
into the bioink66,76-78. Of the tested formulations, the 10:2 L. crispatus-containing gelatin
alginate bioink provided the most accurate line resolution with respect to the specified input
line dimensions, with a difference in line width of only 2.5% between the blank and L.
crispatus-containing 10:2 formulation (Figure 1B).

In addition to the fundamentals of maintaining line resolution, bioprinting also
relies upon parameters such as infill density, extrusion flow rate and pressure, needle
gauge, and layer thickness − which are all contingent on the selected bioink formulation.
To investigate the impact of some of these parameters, blank and probiotic-containing
lattice structures were bioprinted with a variety of thicknesses and diameters (Figure 2AH). From these lattice structures, the 34G needle printed with the greatest precision, evident
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from the achieved infill densities. Overall, it was observed that as the lattice thickness
increased, the variation in scaffold thickness from the input value increased (Figure 2I),
while less variation was seen with changes in the diameter. These results suggest that the
weight and viscosity of the bioink may play a more important role in achieving a nondisperse or high-resolution structure. Similarly, as probiotic concentration increased,
scaffold thickness increased, while the impact on diameter was only observed with high
probiotic loading (blank vs. 109, 8 and 15 mm). Overall and as expected, as scaffold
thickness increases, more variation in structure may be expected, in particular for more
viscous bioinks as seen with L. crispatus-containing bioinks. In our hands we found that
the 107 CFU/mg L. crispatus-containing bioink provided prints most closely aligned with
the thickness input dimensions. Similar to the findings of other studies, these results
indicate that architecture should strive to achieve accurate printing outputs, as prior work
has shown that size deviations may induce more rapid release of active agents 59,106 and
compromised mechanical integrity.

In parallel with measuring the line resolution of bioprinted lattice structures, bioink
viscosity was evaluated to determine the role of the L. crispatus inclusion on printing
resolution. Similar studies with gelatin alginate have found printability within similar
viscosity ranges (~1000 cP) to our 10:2 blank and L. crispatus-containing formulations
with viscosities of 1171 ± 17 cP and 1616 ± 19 cP at 37°C, respectively107-109
(Supplementary Figure 1). Results from our study are in agreement with rheological
studies conducted by other groups that suggest that the viscosity behavior as a function of
temperature defines gelatin alginate as a thermosensitive polymer. Its controlled extrusion
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through fine needles, while maintaining fidelity in shape, indicates that the bioink act as a
non-Newtonian shear thinning fluid63,87,110-112. These characteristics contribute to the
ability to print fine architectures without compromising cell viability when shear rate
changes. Different formulations, including ours and others78,87,88,113 were shown to have
substantial changes in viscosity as function of temperature and concentration, validating
the utility of the 10:2 gelatin alginate formulation for bioprinting.

Another component in maintaining scaffold integrity is the impact of the
crosslinking agent. With this in mind, bioprinted scaffolds were evaluated using different
crosslinkers and crosslinking durations to assess the mechanical integrity of the scaffold
over 28 d. Genipin and CaCl2
respectively

83,85,86,114

are known to crosslink gelatin and sodium alginate,

, however, in our hands, crosslinking with genipin-only resulted in

compromised structural integrity by 7 d (Figure 3A). Similarly, CaCl2-only scaffolds
rapidly degraded within 8 hr. For dual-crosslinked scaffolds, we observed that crosslinking
for 24 hr, maintained the highest level of scaffold integrity over 28 d, both visually and
with 13% less mass loss than scaffolds crosslinked with genipin-only (Figure 3B). These
results suggest that dual-crosslinked scaffolds likely require longer crosslinking times to
fully harden, and to maintain their shape for longer durations.

In parallel with mass loss studies, the swelling of dual-crosslinked scaffolds was
assessed. The dual-crosslinked scaffolds retained more of their initial mass relative to
genipin-only crosslinked scaffolds. However, volumetric measurements were difficult to
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conduct due to minute changes in scaffold thicknesses and diameters. These data suggest
that the scaffold absorbs minimal amounts of surrounding fluid (here, SVF, Figure 3C).

From a cellular perspective, cells incorporated via bioprinting are often susceptible
to a logarithmic-scale reduction in viability, due to shear stress during the extrusion
process61,110. Given this, the post-print viability was evaluated to assess the effect of shear
stress and temperature, resulting from the extrusion process (Figure 4A). Relative to the
unprinted bioink, probiotic viability was maintained for all inclusion concentrations and
curing durations. Furthermore, a macrostructural evaluation of blank and L. crispatuscontaining scaffolds showed scaffold integrity after immersion in SVF for 28 d (Figure
4B), further emphasizing the formulation selection and ability to bioprint L. crispatuscontaining scaffolds with similar processing parameters to blank scaffolds. In addition to
retaining scaffold integrity over 28 d, sustained L. crispatus release was evident through
28 d, culminating in ~5 x 109 CFU/mg (Figure 4C). Moreover, a daily dose of 1 to 4 x 108
CFU/mg was observed through 28 d, demonstrating the potential of the bioprinted scaffolds
to release therapeutically relevant probiotic doses, similar to those observed on a daily basis
with vaginal tablets and creams/gels. These results indicate that L. crispatus remained
metabolically active through 28 d and are additionally supported by fiber eluate pH
measurements, which showed a decrease to vaginally-relevant levels after three to four
days. While lactic acid assays are in the process of being conducted, these pH results
indicate the production of lactic acid from the L. crispatus93,94,97. Hence, the ability to
provide sustained release and probiotic proliferation for 28 d, in combination with
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corresponding pH modulation, may assist in efforts to restore healthy vaginal conditions
and to do so in a way that improves patient adherence.

In addition to assessing probiotic viability and release immediately post-print, the
viability and release of probiotics after storage in different conditions was evaluated
(Figure 5). L. crispatus remained viable after 4 wk storage at -20°C, however storage at
4°C resulted in a reduction in release (viability) relative to the fresh scaffold release. In
contrast, scaffolds stored at room temperature resulted in non-viable probiotics, indicating
that new methods should be considered to improve viability in non-cold chain storage
conditions. Improvement in thermostability may be improved by encapsulating probiotic
into the core of the scaffold, a method similarly used to fabricate electrospun fibers115. The
fabrication and distribution of L. crispatus into the core of the scaffold is confirmed by
cross-sectional SEM images (Figure 6) and the presence of L. crispatus, seen throughout
the scaffold cross-section, provides support for viable proliferation throughout the scaffold,
perhaps relating to the consistency observed in daily release. In combination with
macrostructural images (Figures 3 and 4), dual-crosslinking may help to protect the
scaffold from degradation and likely has a role in retaining viability. However, in the
future, to help increase probiotic viability in more challenging, metabolically-active (room
temperature) storage conditions, additives, such as, xylitol, whey protein, sucrose fatty acid
esters, and primarily, magnesium stearate, may be used to maintain or increase viability,
as shown in previous thermostability studies116,117.
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Additionally, while crosslinking is necessary to maintain the mechanical integrity
of gelatin alginate scaffolds, it can be challenging to find crosslinkers that exert minimal
toxicity on prokaryotic and eukaryotic cells, in particular when cells are printed within the
scaffolds. Moreover finding the ideal combination of bioink and crosslinker can be
challenging and may compromise safety and mechanical integrity. While CaCl2 has been
found to be a cytocompatible crosslinker for alginate83,118, most current methods of gelatin
crosslinking are cytotoxic. Notably, the most popular gelatin crosslinking reagent,
glutaraldehyde, can be toxic if it is biodegraded and released in the body119. In comparison,
genipin has been shown to be a safer alternative to improve the mechanical and thermal
properties of gelatin, as well as prolong its degradation time81. Despite the concurred safety
of genipin, there have been some concerns regarding acute and dose-dependent toxicity120.
For this reason, scaffolds crosslinked with a variety of crosslinking reagents were tested
for cytotoxicity after administration to vaginal epithelial cells (Figure 7). Negligible
toxicity was observed after treatment with genipin-crosslinked and all groups, indicating
preliminary promise in vitro with the concentrations tested. In future studies, it will be
important to evaluate the biocompatibility of bioprinted scaffolds in ex vivo and in vivo
systems. To improve crosslinking formulation, a lower genipin concentrations may be
evaluated to provide an even safer application.

The goals of this study were to develop and characterize a 3D-bioprinted probioticcontaining sustained release intravaginal dosage form. The 10:2 gelatin alginate
formulation, demonstrated fine printing resolution, in addition to mechanical integrity over
28 d. Additionally, bioprinted scaffolds demonstrated high L. crispatus loading, maintained
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viability over different curing and storage conditions, and demonstrated cumulative and
daily release values that are within the range of required dosing for intravaginal
applications. Furthermore, from the preliminary in vitro studies conducted here, vaginal
cell viability was maintained, indicating the potential for 3D-bioprinted scaffolds to
advance to in vitro, ex vivo, and in vivo studies. This study highlights the potential of 3Dbioprinted scaffolds for future female reproductive infections and health applications,
showing promise in providing a new alternative for sustained probiotic delivery.
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